All In Biotech

Drug Trial Radar · NCT03611751

An Investigational Study to Evaluate Experimental Medication BMS-986165 Compared to Placebo and a Currently Available Treatment in Participants With Moderate-to-Severe Plaque Psoriasis

A Multi-Center, Randomized, Double-Blind, Placebo- and Active Comparator-Controlled Phase 3 Study With Randomized Withdrawal and Retreatment to Evaluate the Efficacy and Safety of BMS-986165 in Subjects With Moderate-to-Severe Plaque Psoriasis

Last checked: Nov 19, 2026Latest source record: Dec 20, 2022 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 1,020 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

1,020

Actual

Start

Jul 26, 2018

Primary completion

Nov 29, 2020

Study completion Nov 30, 2020

Sponsor

Lead sponsor
Bristol-Myers SquibbBristol Myers Squibb (BMY)
Sponsor type
Industry
First posted
Aug 2, 2018

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to investigate the experimental medication BMS-986165 compared to placebo and a currently available treatment in participants with moderate to severe plaque psoriasis.

Conditions

  • Psoriasis

Interventions

  • BMS-986165Drug

    Specified dose on specified days

  • PlaceboOther

    Specified dose on specified days

  • ApremilastDrug

    Specified dose on specified days

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. The Number of Participants With a Static Physician's Global Assessment (sPGA) Score of 0 or 1 in Participants Receiving BMS-986165 Compared to Placebo at Week 16 (sPGA 0/1)Time frame: Week 16
  2. The Number of Participants Who Achieve a 75% Improvement From Baseline in the Psoriasis Area and Severity Index (PASI) Score in Participants Receiving BMS-986165 Compared to Placebo at Week 16 (PASI 75)Time frame: Baseline and Week 16

Locations

205 sites in 16 countries. Site status is shown where the registry gives one.

  • Total Skin and Beauty Dermatology Center

    Birmingham, Alabama

  • The Kirklin Clinic of UAB Hospital

    Birmingham, Alabama

  • Alliance Dermatology and Mohs Center - Phoenix

    Phoenix, Arizona

  • Clinical Research Consortium - Tempe

    Tempe, Arizona

  • Johnson Dermatology

    Fort Smith, Arkansas

  • Burke Pharmaceutical Research

    Hot Springs, Arkansas

  • Applied Research Center of Arkansas

    Little Rock, Arkansas

  • Anaheim Clinical Trials

    Anaheim, California

  • Center for Dermatology Clinical Research

    Fremont, California

  • Associates in Research, Inc.

    Fresno, California

  • Marvel Clinical Research

    Huntington Beach, California

  • Interspond - Long Beach Clinical Trials

    Long Beach, California

  • Dermatology Research Associates - Los Angeles

    Los Angeles, California

  • LA Universal Research Center

    Los Angeles, California

  • Artemis Institute for Clinical Research - San Diego

    San Diego, California

  • University of California San Diego Health Systems

    San Diego, California

  • Therapeutics Clinical Research

    San Diego, California

  • San Luis Dermatology and Laser Clinic

    San Luis Obispo, California

  • Artemis Institute for Clinical Research - San Marcos

    San Marcos, California

  • West Coast Research

    San Ramon, California

  • Clinical Science Institute

    Santa Monica, California

  • Synexus - Santa Rosa

    Santa Rosa, California

  • Care Access Research - Walnut Creek

    Walnut Creek, California

  • Stamford Therapeutics Consortium

    Stamford, Connecticut

  • Skin Care Research

    Boca Raton, Florida

  • ERN - Accel Research - Avail

    DeLand, Florida

  • Interspond - Savin Medical Group

    Miami Lakes, Florida

  • Synexus Clinical Research - Saint Petersburg

    Pinellas Park, Florida

  • Progressive Medical Research

    Port Orange, Florida

  • Precision Clinical Research - Corporate Office

    Sunrise, Florida

  • Precision Clinical Research - Corporate Office

    Tamarac, Florida

  • Moore Clinical Research - South Tampa

    Tampa, Florida

  • University of South Florida/USF Health

    Tampa, Florida

  • ForCare Clinical Research

    Tampa, Florida

  • Marietta Dermatology & The Skin Cancer Center

    Marietta, Georgia

  • Advanced Clinical Research - Idaho

    Meridian, Idaho

  • Glazer Dermatology

    Buffalo Grove, Illinois

  • Southern Illinois University School of Medicine

    Springfield, Illinois

  • Dundee Dermatology

    West Dundee, Illinois

  • Dermatology Center of Northwest Indiana

    Crown Point, Indiana

Showing 40 of 205 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.